203 related articles for article (PubMed ID: 9933597)
21. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
[TBL] [Abstract][Full Text] [Related]
22. Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease.
Kuruppu S; Rajapakse NW; Smith AI
Pflugers Arch; 2013 Jul; 465(7):929-34. PubMed ID: 23328864
[TBL] [Abstract][Full Text] [Related]
23. Highly sensitive and selective fluorescence assays for rapid screening of endothelin-converting enzyme inhibitors.
Luciani N; de Rocquigny H; Turcaud S; Romieu A; Roques BP
Biochem J; 2001 Jun; 356(Pt 3):813-9. PubMed ID: 11389689
[TBL] [Abstract][Full Text] [Related]
24. Characterization of phosphoramidon-sensitive metalloproteinases with endothelin-converting enzyme activity in porcine lung membrane.
Sawamura T; Shinmi O; Kishi N; Sugita Y; Yanagisawa M; Goto K; Masaki T; Kimura S
Biochim Biophys Acta; 1993 Feb; 1161(2-3):295-302. PubMed ID: 8431480
[TBL] [Abstract][Full Text] [Related]
25. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations.
Schweizer A; Valdenaire O; Nelböck P; Deuschle U; Dumas Milne Edwards JB; Stumpf JG; Löffler BM
Biochem J; 1997 Dec; 328 ( Pt 3)(Pt 3):871-7. PubMed ID: 9396733
[TBL] [Abstract][Full Text] [Related]
26. A three-dimensional model of endothelin-converting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP).
Bur D; Dale GE; Oefner C
Protein Eng; 2001 May; 14(5):337-41. PubMed ID: 11438756
[TBL] [Abstract][Full Text] [Related]
27. Characterization of PgPepO, a bacterial homologue of endothelin-converting enzyme-1.
Carson JA; Ansai T; Awano S; Yu W; Takehara T; Turner AJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():90S-93S. PubMed ID: 12193062
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
Usmani BA; Harden B; Maitland NJ; Turner AJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():314S-317S. PubMed ID: 12193112
[TBL] [Abstract][Full Text] [Related]
29. Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay.
Ouimet T; Orng SV; Poras H; Gagnidze K; Devi LA; Fournié-Zaluski MC; Roques BP
J Biol Chem; 2010 Nov; 285(45):34390-400. PubMed ID: 20807771
[TBL] [Abstract][Full Text] [Related]
30. Importance of the C-terminal region of big endothelin-1 for specific conversion by phosphoramidon-sensitive endothelin converting enzyme.
Okada K; Takada J; Arai Y; Matsuyama K; Yano M
Biochem Biophys Res Commun; 1991 Oct; 180(2):1019-23. PubMed ID: 1953706
[TBL] [Abstract][Full Text] [Related]
31. Rat big endothelin-1-induced bronchoconstriction and vasoconstriction in the isolated perfused rat lung: role of endothelin converting enzyme and neutral endopeptidase 24.11.
Held HD; Raschak M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):619-24. PubMed ID: 9151301
[TBL] [Abstract][Full Text] [Related]
32. Processing of proendothelin-1 at the C-terminus of big endothelin-1 is essential for proteolysis by endothelin-converting enzyme-1 in vivo.
Kido T; Sawamura T; Hoshikawa H; D'Orléans-Juste P; Denault JB; Leduc R; Kimura J; Masaki T
Eur J Biochem; 1997 Mar; 244(2):520-6. PubMed ID: 9119020
[TBL] [Abstract][Full Text] [Related]
33. Molecular modelling and site-directed mutagenesis of the active site of endothelin-converting enzyme.
Sansom CE; Hoang MV; Turner AJ
Protein Eng; 1998 Dec; 11(12):1235-41. PubMed ID: 9930673
[TBL] [Abstract][Full Text] [Related]
34. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.
Raoch V; Martinez-Miguel P; Arribas-Gomez I; Rodriguez-Puyol M; Rodriguez-Puyol D; Lopez-Ongil S
Br J Pharmacol; 2007 Oct; 152(3):313-22. PubMed ID: 17643133
[TBL] [Abstract][Full Text] [Related]
35. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
Grantham JA; Schirger JA; Wennberg PW; Sandberg S; Heublein DM; Subkowski T; Burnett JC
Circulation; 2000 Apr; 101(16):1976-81. PubMed ID: 10779465
[TBL] [Abstract][Full Text] [Related]
36. A permanent human cell line (EA.hy926) preserves the characteristics of endothelin converting enzyme from primary human umbilical vein endothelial cells.
Ahn K; Pan S; Beningo K; Hupe D
Life Sci; 1995; 56(26):2331-41. PubMed ID: 7791520
[TBL] [Abstract][Full Text] [Related]
37. Endothelin-2-converting enzyme from human renal adenocarcinoma cells is a phosphoramidon-sensitive, membrane-bound metalloprotease.
Shinmi O; Yorimitsu K; Moroi K; Nishiyama M; Sugita Y; Saito T; Inagaki Y; Masaki T; Kimura S
J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S61-4. PubMed ID: 7510000
[TBL] [Abstract][Full Text] [Related]
38. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1.
Xu D; Emoto N; Giaid A; Slaughter C; Kaw S; deWit D; Yanagisawa M
Cell; 1994 Aug; 78(3):473-85. PubMed ID: 8062389
[TBL] [Abstract][Full Text] [Related]
39. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
Lin CL; Winardi W; Jeng AY; Kwan AL
Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
[TBL] [Abstract][Full Text] [Related]
40. Lactoferricin B-derived peptides with inhibitory effects on ECE-dependent vasoconstriction.
Fernández-Musoles R; López-Díez JJ; Torregrosa G; Vallés S; Alborch E; Manzanares P; Salom JB
Peptides; 2010 Oct; 31(10):1926-33. PubMed ID: 20600419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
